A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Latest Information Update: 22 Mar 2024
At a glance
- Drugs XMT-1660 (Primary)
- Indications Advanced breast cancer; Endometrial cancer; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Mersana Therapeutics
- 28 Feb 2024 According to Mersana media release, company ,Enrollment is expected to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024.
- 21 Feb 2024 Planned number of patients changed from 166 to 319.
- 21 Feb 2024 Planned End Date changed from 1 Jan 2026 to 1 May 2027.